An update from Beyond Air ( (XAIR) ) is now available.
On March 14, 2025, Ron Bentsur resigned from the board of directors of Beyond Air, Inc., with no disagreements with the company cited as the reason. On March 11, 2025, Beyond Air announced the expansion of its global distribution channels for the LungFit PH system with new agreements in France, Romania, Turkey, and Morocco, increasing its international reach to 18 countries. This expansion is expected to accelerate the commercial ramp-up of LungFit PH internationally, leveraging established medical device infrastructure and positive feedback from U.S. hospitals.
More about Beyond Air
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to improve the lives of patients with respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval and CE Mark for its LungFit PH system, designed for treating neonates with hypoxic respiratory failure, and is advancing other LungFit systems in clinical trials for severe lung infections.
YTD Price Performance: -30.56%
Average Trading Volume: 1,634,168
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $22.51M
Learn more about XAIR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com